Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q2 FY19 results · Jul–Sep 2018
Jubilant Pharmova reported revenue from operations of ₹2,269.49 crore and net profit of ₹209.77 crore for Q2 FY19 (Jul–Sep 2018), on a consolidated basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,269.49 | — | — | 2,078.65 | +9.2% |
| Other income | 3.83 | — | — | 9.47 | −59.6% |
| Total income | 2,273.32 | — | — | 2,088.12 | +8.9% |
| Profit before tax | 301.81 | — | — | 286.37 | +5.4% |
| Net profit for the period | 209.77 | — | — | 200.37 | +4.7% |
| Attributable to shareholders of the company | 210.41 | — | — | 202.50 | +3.9% |
| EPS, basic (₹) | 13.50 | — | — | 13.00 | +3.8% |
| Net margin (%) | 9.2 | — | 9.6 |
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 887.27 | — | — | 826.64 | +7.3% |
| Other income | 63.80 | — | — | 4.41 | 14x |
| Total income | 951.07 | — | — | 831.05 | +14.4% |
| Profit before tax | 91.21 | — | — | 33.45 | +172.7% |
| Net profit for the period | 79.61 | — | — | 23.88 | +233.4% |
| EPS, basic (₹) | 5.00 | — | — | 1.50 | +233.3% |
| Net margin (%) | 9.0 | — | 2.9 |
Consolidated
- Filed with BSE
- 23 Oct 2018, 15:15 IST
- Board meeting
- 22 Oct 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Oct 2018, 15:15 IST
- Board meeting
- 22 Oct 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE